Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.

Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, Invernizzi P.

Cells. 2020 Mar 11;9(3). pii: E688. doi: 10.3390/cells9030688. Review.

2.

Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.

Sala L, Mancin M, Pastore A, Seminati D, Cortinovis D, Bidoli P, Alberti A.

Lung Cancer. 2020 Apr;142:120-122. doi: 10.1016/j.lungcan.2020.02.019. Epub 2020 Feb 28.

PMID:
32145595
3.

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.

Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.

Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020.

4.

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.

Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R.

J Thorac Oncol. 2020 Mar;15(3):416-425. doi: 10.1016/j.jtho.2019.11.023. Epub 2019 Dec 5.

PMID:
31812754
5.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.

Landi L, D'Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabro' L, Cappuzzo F.

J Immunother Cancer. 2019 Nov 21;7(1):316. doi: 10.1186/s40425-019-0793-8.

6.

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.

Sharma GG, Cortinovis D, Agustoni F, Arosio G, Villa M, Cordani N, Bidoli P, Bisson WH, Pagni F, Piazza R, Gambacorti-Passerini C, Mologni L.

J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028. No abstract available.

PMID:
31668326
7.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

8.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Nov;24(11):e1165-e1171. doi: 10.1634/theoncologist.2018-0737. Epub 2019 Apr 17.

9.

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN.

Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9.

PMID:
30967420
10.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A.

Lung Cancer. 2019 Mar;129:35-40. doi: 10.1016/j.lungcan.2018.12.025. Epub 2019 Jan 15.

PMID:
30797489
11.

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Abbate MI, Cortinovis DL, Tiseo M, Vavalà T, Cerea G, Toschi L, Canova S, Colonese F, Bidoli P.

Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25. Review.

PMID:
30681378
12.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.

Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhász E, Kowalski D, Robinet G, Cadranel J, Bidoli P, Chung J, Fritsch A, Drews U, Wagner A, Govindan R.

J Thorac Oncol. 2019 Apr;14(4):701-711. doi: 10.1016/j.jtho.2019.01.010. Epub 2019 Jan 21. Erratum in: J Thorac Oncol. 2019 Aug;14(8):1484.

PMID:
30677506
13.

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassineti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

14.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.

Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.

15.

Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse.

Cortinovis D, Canova S, Abbate MI, Colonese F, Cogliati V, Bidoli P.

Future Oncol. 2018 Sep;14(22):2303-2317. doi: 10.2217/fon-2018-0066. Epub 2018 Aug 8. Review.

PMID:
30088419
16.

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.

Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME.

Oncotarget. 2018 Jun 8;9(44):27448-27459. doi: 10.18632/oncotarget.25422. eCollection 2018 Jun 8.

17.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

18.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
19.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. Epub 2018 May 2.

PMID:
29721850
20.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
21.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M.

Lung Cancer. 2017 Oct;112:181-187. doi: 10.1016/j.lungcan.2017.07.038. Epub 2017 Aug 5.

22.

A new race against lung cancer.

Cortinovis D, Canova S, Abbate MI, Colonese F, Bidoli P.

J Vis Surg. 2017 Aug 21;3:110. doi: 10.21037/jovs.2017.07.01. eCollection 2017. No abstract available.

23.

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group.

Ann Oncol. 2017 Sep 1;28(9):2206-2212. doi: 10.1093/annonc/mdx299.

24.

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.

Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F.

Ann Oncol. 2017 Oct 1;28(10):2547-2551. doi: 10.1093/annonc/mdx315.

25.

FOLFOX4/XELOX in stage II-III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial.

Labianca R, Mucciarini C, Bidoli P, Corsi D, Montesarchio V, Bochicchio Anna M, Iaffaioli V, Ciarlo A, De Placido S, Amoroso D, Cortesi E, Daniele B, Amadori D, Turci D, Pelliccioni S, Cinieri S, Ravaioli A, Piazza E, Rulli E, Sobrero A.

Ann Oncol. 2017 Jun;28 Suppl 3:iii147. doi: 10.1093/annonc/mdx262.024. No abstract available.

26.

EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.

DE Marinis F, Bidoli P, Luciani A, Amoroso D, Tonini G, Bertolini A, Brandes AA, Migliorino MR, Favaretto A, Gridelli C.

Anticancer Res. 2017 May;37(5):2457-2464.

PMID:
28476814
27.

Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.

Fabbri A, Cossa M, Sonzogni A, Bidoli P, Canova S, Cortinovis D, Abbate MI, Calabrese F, Nannini N, Lunardi F, Rossi G, La Rosa S, Capella C, Tamborini E, Perrone F, Busico A, Capone I, Valeri B, Pastorino U, Albini A, Pelosi G.

Virchows Arch. 2017 Jul;471(1):31-47. doi: 10.1007/s00428-017-2130-2. Epub 2017 Apr 27.

PMID:
28451756
28.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
29.

Focus on Nivolumab in NSCLC.

Cortinovis DL, Canova S, Abbate M, Colonese F, Bidoli P.

Front Med (Lausanne). 2016 Dec 13;3:67. doi: 10.3389/fmed.2016.00067. eCollection 2016. Review.

30.

Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.

Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P, Cortinovis DL.

Tumori. 2017 Mar 24;103(2):143-147. doi: 10.5301/tj.5000584. Epub 2016 Nov 28.

PMID:
28009425
31.

Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.

Gridelli C, Chella A, Valmadre G, Allegrini G, Brighenti M, Bidoli P, Rossi A, Maione P, Migliorino MR, Ricciardi S, DE Marinis F.

Anticancer Res. 2016 Dec;36(12):6535-6540.

PMID:
27919979
32.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
33.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

34.

Comment on: "Is there a role for vitamin D in human reproduction?"

Colonese F, La Rosa VL, Laganà AS, Vitale SG, Cortinovis D, Bidoli P.

Horm Mol Biol Clin Investig. 2017 Jan 1;29(1):37-38. doi: 10.1515/hmbci-2016-0040. No abstract available.

PMID:
27740917
35.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

36.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
37.

Targeted therapies and immunotherapy in non-small-cell lung cancer.

Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S.

Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. Review.

38.

Interpretation of lung cancer study outcomes.

Cortinovis D, Abbate M, Bidoli P, Pelizzoni D, Canova S.

J Thorac Dis. 2015 Nov;7(11):E541-7. doi: 10.3978/j.issn.2072-1439.2015.11.26.

39.

What are the options for non-small-cell lung cancer patients post second-line therapy?

Cortinovis DL, Canova S, Bidoli P.

Future Oncol. 2015;11(17):2379-82. doi: 10.2217/FON.15.159. Epub 2015 Aug 13. Review. No abstract available.

PMID:
26270000
40.

Isolated cardiac metastasis from squamous cell esophageal cancer.

Abbate MI, Cicchiello F, Canova S, Cortinovis D, Mariani S, Maffini F, Bidoli P.

Tumori. 2015 Jul 24;101(4):e118-21. doi: 10.5301/tj.5000324.

PMID:
26045127
41.

C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool: an observational study.

Jaconi M, Pagni F, Vacirca F, Leni D, Corso R, Cortinovis D, Bidoli P, Bono F, Cuttin MS, Valente MG, Pesci A, Bedini VA, Leone BE.

Medicine (Baltimore). 2015 Mar;94(12):e698. doi: 10.1097/MD.0000000000000698.

42.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.

PMID:
25605838
43.

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

Cappuzzo F, Finocchiaro G, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.

J Thorac Oncol. 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442.

44.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C.

Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21.

45.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M.

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.

PMID:
24933332
46.

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.

Ann Oncol. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12.

47.

Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue.

Alberti P, Cortinovis D, Frigeni B, Bidoli P, Cavaletti G.

Pain Manag. 2013 Nov;3(6):417-9. doi: 10.2217/pmt.13.57. No abstract available.

PMID:
24654894
48.

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study.

Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P.

Int J Breast Cancer. 2014;2014:769790. doi: 10.1155/2014/769790. Epub 2014 Jan 16.

49.

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.

Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, Caprioni F, Villa F, Mosconi S, Faloppi L, Tonini G, Boni C, Conte P, Di Costanzo F, Cinquini M; Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Dig Liver Dis. 2014 Feb;46(2):182-6. doi: 10.1016/j.dld.2013.09.020. Epub 2013 Nov 2.

PMID:
24189171
50.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.

J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.

PMID:
23835707

Supplemental Content

Loading ...
Support Center